Life sci:舒马曲坦抑制卵清蛋白诱导的过敏性鼻炎研究

2019-10-23 AlexYang MedSci原创

过敏性鼻炎是一种全球性的致残性疾病,可以由气道炎症来鉴定。舒马曲坦是一种5-羟色胺1B/1D(5HT1B/1D)兴奋剂,并且作为偏头痛的治疗药物。5HT1B/1D受体的激活能够抑制神经肽的释放并抑制炎症途径。最近,有研究人员调查了舒马曲坦对卵清蛋白诱导的过敏性鼻炎小鼠模型的影响以及一氧化氮的角色。研究发现,腹腔注射舒马曲坦能够明显的减少过敏性小鼠鼻痒和IL-4以及血清lgE的水平,但是能够增加IF

过敏性鼻炎是一种全球性的致残性疾病,可以由气道炎症来鉴定。舒马曲坦是一种5-羟色胺1B/1D(5HT1B/1D)兴奋剂,并且作为偏头痛的治疗药物。5HT1B/1D受体的激活能够抑制神经肽的释放并抑制炎症途径。最近,有研究人员调查了舒马曲坦对卵清蛋白诱导的过敏性鼻炎小鼠模型的影响以及一氧化氮的角色。

研究发现,腹腔注射舒马曲坦能够明显的减少过敏性小鼠鼻痒和IL-4以及血清lgE的水平,但是能够增加IFNγ的水平。组织病理学分析表明了嗜酸性粒细胞的数目在卵清蛋白诱导的过敏性小鼠鼻粘膜上显著提高,而舒马曲坦治疗能够显著的减少嗜酸性粒细胞的数目。GR-127935是一种选择性的5-HT1B/1D受体拮抗剂,能够逆转舒马曲坦的抗过敏性作用。急性给药I-NAME(一种非特异性的舒马曲坦合成酶抑制剂)以及舒马曲坦能够减弱舒马曲坦的抗过敏性作用,但是慢性给药I-NAME则不能产生上述作用。更多的是,舒马曲坦能够减少诱导性一氧化氮合成酶(iNOS)蛋白的表达,但是并不改变eNOS蛋白的浓度。

最后,研究人员指出,他们的研究表明了舒马曲坦给药与抗炎症效果相关,并通过5HT1B/1D受体实现。iNOS表达的减少和辅助性T1和2细胞因子水平的变化可能表明了诱导性NOS和炎症的参与。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1650271, encodeId=f33f16502e1a5, content=<a href='/topic/show?id=b5de3690069' target=_blank style='color:#2F92EE;'>#卵清蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36900, encryptionId=b5de3690069, topicName=卵清蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=430623995054, createdName=gostraight, createdTime=Fri Jun 05 20:42:00 CST 2020, time=2020-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047176, encodeId=81d6204e17629, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sat Dec 14 18:42:00 CST 2019, time=2019-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068608, encodeId=3dc92068608d7, content=<a href='/topic/show?id=59371088215' target=_blank style='color:#2F92EE;'>#Life#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10882, encryptionId=59371088215, topicName=Life)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Fri Nov 15 15:42:00 CST 2019, time=2019-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374340, encodeId=18833e43404b, content=学习了,长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Thu Oct 24 21:22:43 CST 2019, time=2019-10-24, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1650271, encodeId=f33f16502e1a5, content=<a href='/topic/show?id=b5de3690069' target=_blank style='color:#2F92EE;'>#卵清蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36900, encryptionId=b5de3690069, topicName=卵清蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=430623995054, createdName=gostraight, createdTime=Fri Jun 05 20:42:00 CST 2020, time=2020-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047176, encodeId=81d6204e17629, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sat Dec 14 18:42:00 CST 2019, time=2019-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068608, encodeId=3dc92068608d7, content=<a href='/topic/show?id=59371088215' target=_blank style='color:#2F92EE;'>#Life#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10882, encryptionId=59371088215, topicName=Life)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Fri Nov 15 15:42:00 CST 2019, time=2019-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374340, encodeId=18833e43404b, content=学习了,长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Thu Oct 24 21:22:43 CST 2019, time=2019-10-24, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1650271, encodeId=f33f16502e1a5, content=<a href='/topic/show?id=b5de3690069' target=_blank style='color:#2F92EE;'>#卵清蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36900, encryptionId=b5de3690069, topicName=卵清蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=430623995054, createdName=gostraight, createdTime=Fri Jun 05 20:42:00 CST 2020, time=2020-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047176, encodeId=81d6204e17629, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sat Dec 14 18:42:00 CST 2019, time=2019-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068608, encodeId=3dc92068608d7, content=<a href='/topic/show?id=59371088215' target=_blank style='color:#2F92EE;'>#Life#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10882, encryptionId=59371088215, topicName=Life)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Fri Nov 15 15:42:00 CST 2019, time=2019-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374340, encodeId=18833e43404b, content=学习了,长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Thu Oct 24 21:22:43 CST 2019, time=2019-10-24, status=1, ipAttribution=)]
    2019-11-15 clmlylxy
  4. [GetPortalCommentsPageByObjectIdResponse(id=1650271, encodeId=f33f16502e1a5, content=<a href='/topic/show?id=b5de3690069' target=_blank style='color:#2F92EE;'>#卵清蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36900, encryptionId=b5de3690069, topicName=卵清蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=430623995054, createdName=gostraight, createdTime=Fri Jun 05 20:42:00 CST 2020, time=2020-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047176, encodeId=81d6204e17629, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sat Dec 14 18:42:00 CST 2019, time=2019-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068608, encodeId=3dc92068608d7, content=<a href='/topic/show?id=59371088215' target=_blank style='color:#2F92EE;'>#Life#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10882, encryptionId=59371088215, topicName=Life)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Fri Nov 15 15:42:00 CST 2019, time=2019-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374340, encodeId=18833e43404b, content=学习了,长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Thu Oct 24 21:22:43 CST 2019, time=2019-10-24, status=1, ipAttribution=)]
    2019-10-24 1ddf0692m34(暂无匿称)

    学习了,长知识

    0

相关资讯

Immunotherapy:舌下免疫治疗对屋尘螨诱导的过敏性鼻炎和并发症的疗效分析

最近,有研究人员调查了舌下免疫治疗对尘螨诱导的过敏性鼻炎和其过敏性并发症的影响。研究是一个前瞻性的案例对照研究,包括了120名患者(案例80,对照40),调查持续的时间为12个月。研究发现,舌下免疫治疗能够在尘螨诱导的过敏性鼻炎中减少53.65%的总鼻炎症状(p<0.0001),但在对照中不存在上述情况(-7.3%, p=0.99)。总症状评分中的并发哮喘评分从17.79减少到了8.8(p&

Ear Nose Throat J:α-乙酸生育酚在鼻呼吸功能作用研究

原发性萎缩性鼻炎是一种鼻部和副鼻窦疾病,并具有鼻腔和副鼻窦粘膜功能的渐进性丧失特征,病因是由于纤毛粘膜上皮逐渐破坏、浆液腺体萎缩和骨结构丢失。最近有研究人员基于主观和客观数据,评估了α-乙酸生育酚(维生素E)在原发性萎缩性鼻炎治疗中的影响。研究人员分析了α-乙酸生育酚治疗前后6个月的鼻内镜下鼻粘膜核、鼻前鼻测定仪和鼻黏膜睫状体清除术情况。研究人员使用成对样本t测试(95%CI,P<0.05)

J Ethnopharmacol:黑沙蒿提取物治疗过敏性鼻和鼻窦炎民族医学研究

在传统中医/蒙古医学中,黑沙蒿(AOK)已经用于风湿性关节炎,冷头痛,喉咙痛的治疗,并且还被当地的"赤脚医生"用于鼻窦炎的治疗。到目前为止,该药物的治疗机制仍旧不清楚。最近,有研究人员评估了AOK提取物的体内抗炎症作用和过敏性鼻炎(AR)减弱效果,以及体外抗微生物活性,从而来确定其治疗机制。在耳朵肿胀模型中,95%乙醇乙酸乙酯层提取物(100.00 mg/kg)表现出了比阳性对照(地塞米松,191

Int Arch Allergy Immunol:PAI-1基因多样性与过敏性疾病风险的增加相关

近些年,许多研究关注于纤溶酶原激活物抑制剂(PAI)-1基因4G/5G的多态性与过敏性疾病的风险之间的相关性,但是结果并不一致。最近,有研究人员进行了元分析来研究PAI-1多态性与过敏性疾病易感性之间的相关性。元分析共包括了14个之前的研究,共包括了2327个案例和2838个对照。总之,研究人员发现PAI-1多态性与过敏性疾病的风险存在明显的相关性(4G/4G+4G/5G vs. 5G/5G: O

Scand J Immunol:过敏性鼻炎患者中PD-1/PD-L1途径的阻断能够促进CD19+ CD25+ Bregs细胞凋亡和抑制IL-10的分泌

PD-1/PD-L1途径对免疫调控是非常重要的,该途径能够控制T细胞耐性和活性的平衡。然而,PD-1/PD-L1图U经与调控B细胞(Bregs)之间的相关性在过敏性鼻炎中还没有全面的调查。最近,有研究人员使用流式细胞术在健康对照和过敏性鼻炎患者中检测了外周CD19+ CD25+ Bregs数目和该类型细胞中的IL-10表达水平。之后,研究人员评估了PD-L1在CD19+ CD25+ Bregs中的

Int Forum Allergy Rhinol:非囊性纤维化性支气管扩张患者的慢性鼻窦炎的患病率和鉴定

慢性鼻窦炎(CRS)与支气管扩张相关;然而,该相关性在美国(US)人群中仍没有很好的研究。最近,有研究人员确定了CRS在患有支气管扩张患者中的流行度情况,并鉴定了哪一种并发疾病与支气管扩张患者的CRS的存在相关。研究是一个回顾性的群体研究,数据从一个大的数据库中获得。研究人员鉴定了2007年到2017年患有支气管扩张的患者。研究人员根据伴随的CRS的有无将患者分成了2个群体。特征鉴定分析包括了人口